Investigational drug slows metastatic breast cancer progression
13:15 EDT 11 Jun 2012 | The Medical News
Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Onco..
Original Article: Investigational drug slows metastatic breast cancer progression
More From BioPortfolio on "Investigational drug slows metastatic breast cancer progression"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
